Frontlight ResearchEarly access
CompletedPhase 4
Zoster Eye Disease Study
Key facts
- Who runs it
- NYU Langone Health
- Where
- Albany, Ann Arbor, Atlanta, Aurora, Bala-Cynwyd, Baltimore, Bethesda, Birmingham, Boston, Canandaigua, Chicago, Cincinnati, Cleveland, Dallas, Danville, Delray Beach, Durham, East Setauket, Fort Worth, Gainesville, Glenview, Golden Valley, Grand Rapids, Great Neck, Houston, Indianapolis, Jacksonville, La Jolla, Lebanon, Lexington, Little Rock, Littleton, Loma Linda, Los Angeles, Madison, Memphis, Miami, Minnetonka, Morristown, Nashville, New Orleans, New York, Owings Mills, Palo Alto, Peabody, Philadelphia, Portland, Prairie Village, Richmond, Rochester, Salt Lake City, San Antonio, San Francisco, San Luis Obispo, Scottsdale, Seattle, Shreveport, St Louis, Washington D.C., and Weymouth, United StatesSee the 70 sitesAlso in 1 other country, 7 sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 527 people enrolled
- Started
- 23 Aug 2017
- Ended
- 22 Jul 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Masked Placebo
- Masked Oral Valacyclovir
- Record updated
- 7 March 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Other criteria
- PARTICIPANT INCLUSION CRITERIA
- To be eligible for study participation, an individual must meet all of the following criteria:
- Ability to understand, and willingness and ability to read and sign, the informed consent form
- Ability to understand and follow instructions and study procedures
- Willingness to comply with all study procedures and be available for the duration of the study
- Ability to take oral medication, and are willing to adhere to study medication regimen
- Age 18 years or older
- Diagnosed with HZO in one eye based on both of these criteria:; History of characteristic unilateral, usually vesicular, HZO rash in the dermatomal distribution of cranial nerve V1 or V2; Medical record documentation of an episode of active dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis due to HZO within the preceding year. This episode of active anterior segment ocular disease may be due to HZO of recent onset (within the preceding 6 months); or chronic HZO (with onset six or more months ago); may be new, worsening, or recurrent disease after a period of inactivity; and may occur after medication was reduced; Study participants with chronic HZO must be on a stable treatment regimen and off antivirals for at least 30 days before enrollment. Study participants with chronic HZO who do not meet this criterion may be rescreened, if they are able to meet this criterion within 3 months after the study visit. This is not a requirement for study participants with recent onset HZO, who may be enrolled at any time, preferably after completing recommended acute antiviral treatment, if prescribed, is completed. They can be on variable dose of steroids, and only need to be off oral and topical antivirals by the enrollment visit
- For females with reproductive potential, willingness to use highly effective contraception (e.g., hormonal contraception, barrier contraception, intrauterine device, or abstinence); PARTICIPANT EXCLUSION CRITERIA; An individual who meets any of the following criteria will be excluded from participation in this study:
- History of immunocompromised status as defined by current CDC contraindications for the vaccine against zoster (44); Study participants who are diagnosed with leukemia, lymphomas or other malignant neoplasms affecting bone marrow or lymphatic system, unless leukemia in remission and off chemotherapy for at least 3 months; Study participants who are diagnosed with Acquired Immune Deficiency Syndrome (AIDS) or presents with other clinical manifestations of Human Immunodeficiency virus (HIV) including CD4 count of ≤ 200 cells/ml; Study participants on immunosuppressive therapy including:; High-dose corticosteroids (greater than equivalent of prednisone 20 mg/day within 1 month) ii. Chemotherapy, other than low dose used for treatment of immune-mediated diseases within 3 months iii. Study participants receiving recombinant human immune mediators and immune modulators, especially antitumor necrosis agents, within 1 month prior to enrollment d. Study participants with unspecified cellular immunodeficiency. e. Study participants with history of hematopoietic stem cell transplantation
- Medical history of a systemic disease and thought likely to meet one of the exclusion criteria listed in exclusion criterion #1 during the 18-month study period
- Renal insufficiency:; Requires dialysis or has history of renal transplant or; eGFR less than 45, determined within 3 months days preceding enrollment
- Allergy or adverse reaction to valacyclovir or acyclovir
- History of vaccination against zoster within one month prior to enrollment. Study participants who meet this exclusion criterion may be may be screened and enrollment delayed until eligible within 3 months. If the study participant receives the Herpes Zoster Subunit vaccine (Recombinant Zoster Vaccine (RZV), Shingrix), rescreening should take place one month after the second required dose of the vaccine
- Keratorefractive surgery, other than limbal relaxing incisions or astigmatic keratotomies at the time of cataract surgery, within 5 years of enrollment, or keratoplasty of the involved eye with zoster
- On systemic antivirals with activity against herpes within the past 30 days, including acyclovir, valacyclovir, or famciclovir, for any reason except for treatment of recent onset HZO, including investigational drug trial
- History of another condition that may require treatment with one of these three antivirals listed above in exclusion criterion #7, during the course of the study; study participants who require chronic suppressive antiviral treatment with these medications will be excluded
- Sexually active women who are pregnant, nursing, or in their reproductive years who do not agree to use contraception during the 1-year treatment period
- Incarceration
- Any condition or circumstance that in the opinion of the study investigator, would place the study participant in increased risk or affect his/her full compliance or completion of the study
- Participation in a clinical study testing a drug, biologic, device or other intervention within the last 30 days from enrollment visit. Study participants who meet this criterion may be rescreened
Where in United States
Also in 1 other country, 7 sites
- Albany Stratton VA Medical CenterAlbany, United States
- University of MichiganAnn Arbor, United States
- Eye Consultants of Atlanta, PCAtlanta, United States
- University of ColoradoAurora, United States
- Vantage Eye Care Center, LLCBala-Cynwyd, United States
- The Krieger Eye InstituteBaltimore, United States
- University of MarylandBaltimore, United States
- Wilmer Eye Institute John HopkinsBethesda, United States
- University of Alabama at BirminghamBirmingham, United States
- Boston Medical CenterBoston, United States
- Massachusetts Eye and Ear InfirmaryBoston, United States
- Tufts Medical CenterBoston, United States
- Finger Lakes Ophthalmology /The Eye Care CenterCanandaigua, United States
- University of IllinoisChicago, United States
- Cincinnati Eye InstituteCincinnati, United States
- Case Western Reserve UniversityCleveland, United States
- Cornea Associates of TexasDallas, United States
- University of Texas, SouthwesternDallas, United States
- Geisinger Eye ClinicDanville, United States
- Delray Eye Associates, PADelray Beach, United States
- Duke UniversityDurham, United States
- Stony Brook OphthalmologyEast Setauket, United States
- Cornea Consultants of TexasFort Worth, United States
- University of FloridaGainesville, United States
- Northshore University Health SystemGlenview, United States
- Northwest Eye ClinicGolden Valley, United States
- Verdier Eye CenterGrand Rapids, United States
- Northwell HealthGreat Neck, United States
- Alkek Eye Center - Baylor College of MedicineHouston, United States
- Indiana University - Glick Eye InstituteIndianapolis, United States
- Florida Eye SpecialistsJacksonville, United States
- Scripps ClinicLa Jolla, United States
- Dartmouth Hitchcock Medical CenterLebanon, United States
- University of KentuckyLexington, United States
- University of Arkansas for Medical SciencesLittle Rock, United States
- Colorado Cornea Consultants P.C.Littleton, United States
- Loma Linda University Eye InstituteLoma Linda, United States
- Jules Stein Eye Clinic - UCLALos Angeles, United States
- University of Wisconsin - MadisonMadison, United States
- University of Tennessee - Hamilton Eye InstituteMemphis, United States
- University of Miami, Bascom Palmer Eye InstituteMiami, United States
- Jennifer BurdickMinnetonka, United States
- EyeCare MD of NJMorristown, United States
- Cornea and Cataract Consultants of NashvilleNashville, United States
- Vanderbilt Eye InstituteNashville, United States
- LSU Health Science CenterNew Orleans, United States
- New York Eye and Ear InfirmaryNew York, United States
- NYU Langone HealthNew York, United States
- Weill Cornell OphthalmologyNew York, United States
- Crossroads Eye PhysicianOwings Mills, United States
- Byers Eye Institute at Stanford UniversityPalo Alto, United States
- Lahey Medical CenterPeabody, United States
- Corneal Associates at Wills Eye HospitalPhiladelphia, United States
- University of PennsylvaniaPhiladelphia, United States
- Casey Eye Institute, Oregon Health and Science UniversityPortland, United States
- Devers Eye InstitutePortland, United States
- University of Kansas Medical CenterPrairie Village, United States
- Virginia Eye InstituteRichmond, United States
- Mayo ClinicRochester, United States
- University of Utah, Moran Eye CenterSalt Lake City, United States
- R and R Eye Research, LLCSan Antonio, United States
- UCSF- Francis I. Proctor FoundationSan Francisco, United States
- Pacific Eye Surgeons, Inc.San Luis Obispo, United States
- Mayo Clinic - ArizonaScottsdale, United States
- NY Eye SurgeonsSeattle, United States
- Virginia Mason Medical CenterSeattle, United States
- Shreveport Eye ClinicShreveport, United States
- Washington University OpthalmologySt Louis, United States
- MedStar Georgetown University HospitalWashington D.C., United States
- Eye Health ServicesWeymouth, United States
About the trial
What the trial wants to find out
This is a multi-center, randomized, double-masked, placebo-controlled clinical trial of suppressive valacyclovir for one year in immunocompetent study participants with an episode of dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis due to Herpes Zoster Ophthalmicus (HZO) in the year prior to enrollment.
The 2 groups in the trial
- PlaceboPlacebo, for comparison
Encapsulated masked placebo
Treatment: Masked Placebo
- Masked Oral Valacyclovir 1000 mg dailyExisting treatment, for comparison
Valacyclovir, 500 mg, oral pill, two 500mg pills daily
Treatment: Masked Oral Valacyclovir
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus
- Publications
- Time-Varying Effects of Valacyclovir Prophylaxis in the Zoster Eye Disease Study: A Post Hoc Exploratory Analysis of a Randomized Clinical Trial.JAMA ophthalmology, 2026
- Outcomes of Recombinant Zoster Vaccination in Herpes Zoster Ophthalmicus: A Secondary Analysis of the Zoster Eye Disease Study.Cornea, 2026
- Low-Dose Valacyclovir for Postherpetic Neuralgia in the Zoster Eye Disease Study: A Randomized Clinical Trial.JAMA ophthalmology, 2025
- Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus: The Zoster Eye Disease Randomized Clinical Trial.JAMA ophthalmology, 2025
- Baseline Participant Characteristics at Enrollment in the Zoster Eye Disease Study.Cornea, 2024
- Zoster Eye Disease Study: Rationale and Design.Cornea, 2022
- Record updated
- 7 March 2025